Latest news

• Pharma sales help Bayer escape the worst from a bumpy 2017

  But those failures were tempered by positive results late in the year for larotrectinib, one of two cancer assets licensed from Loxo Oncology in a $1.5bn deal. ... Larotrectinib is expected to be filed for US approval within the coming weeks, and the

• Roche buys cancer company Ignyta for $1.7bn

  That high level of response was behind Bayer’s decision to stump up $1.55bn to license Loxo’s larotrectinib, which is also in phase II basket trials involving patients with

• Bayer gets clinical data to support $1.5bn Loxo deal

  Bayer gets clinical data to support $1.5bn Loxo deal. Larotrectinib’s response rate likely to be practice changing. ... Larotrectinib’s near universal response rate and compelling durability of response in paediatric patients with TRK fusion cancers

• Joerg Moeller to head Bayer R&D after operational shake-up

  Among the highlights on the agenda are a look at its emerging cancer pipeline, including Loxo-sourced TRK inhibitors larotrectinib and LOXO-195 as well as projects in oncogenic signalling,

• Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

  In the ASCO trials, larotrectinib achieved a 76% objective response rate in 50 patients - both adults and children - diagnosed with 17 types of TRK fusion protein-positive advanced cancer. ... LOXO-195 seems to have activity in cancers that acquire